This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services E-mail this article to a friend Similar articles in this journal Similar articles in ASM journals Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by al-Sibai, M B Articles by Qadri, S M Search for Related Content PubMed PubMed Citation Articles by al-Sibai, M B Articles by Qadri, S M

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1992 January; 36(1): 150-152

Efficacy of ciprofloxacin for treatment of Brucella melitensis infections.

M B al-Sibai, M A Halim, M M el-Shaker, B A Khan and S M Qadri

King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.

ABSTRACT

The effectiveness of treatment of human brucellosis caused by Brucella melitensis with ciprofloxacin alone was investigated in a prospective nonrandomized study. Subjects with central nervous system involvement, endocarditis, or severe renal dysfunction; children under 16 years of age; and pregnant women were excluded from the study. Of 19 patients, 16 completed the study; 7 were diagnosed as having acute systemic brucellosis, and 9 had acute brucella arthritis-diskitis. A rapid response to ciprofloxacin was seen in all 16 patients, but the blood cultures of 1 patient remained positive and the treatment was changed. During a 104-week follow-up period, 4 of the 15 responding patients relapsed or were reinfected within 8 to 32 weeks after completion of therapy. We conclude that treatment with ciprofloxacin alone, although effective for the acute symptoms, is associated with an appreciable rate of relapse; therefore, it should be given with other agents for treatment of brucellosis.

---

Antimicrob Agents Chemother. 1992 January; 36(1): 150-152

This article has been cited by other articles:

• Posadas, D. M., Martin, F. A., Sabio y Garcia, J. V., Spera, J. M., Delpino, M. V., Baldi, P., Campos, E., Cravero, S. L., Zorreguieta, A. (2007). The TolC Homologue of Brucella suis Is Involved in Resistance to Antimicrobial Compounds and Virulence. Infect. Immun. 75: 379-389 [Abstract] [Full Text]  
• Falagas, M. E., Bliziotis, I. A. (2006). Quinolones for Treatment of Human Brucellosis: Critical Review of the Evidence from Microbiological and Clinical Studies. Antimicrob. Agents Chemother. 50: 22-33 [Full Text]  
• Braibant, M., Guilloteau, L., Zygmunt, M. S. (2002). Functional Characterization of Brucella melitensis NorMI, an Efflux Pump Belonging to the Multidrug and Toxic Compound Extrusion Family. Antimicrob. Agents Chemother. 46: 3050-3053 [Abstract] [Full Text]  
• Akova, M., Gur, D., Livermore, D. M., Kocagoz, T., Akalin, H. E. (1999). In Vitro Activities of Antibiotics Alone and in Combination against Brucella melitensis at Neutral and Acidic pHs. Antimicrob. Agents Chemother. 43: 1298-1300 [Abstract] [Full Text]  
• Trujillano-Martin, I., Garcia-Sanchez, E., Martinez, I. M., Fresnadillo, M. J., Garcia-Sanchez, J. E., Garcia-Rodriguez, J. A. (1999). In Vitro Activities of Six New Fluoroquinolones against Brucella melitensis. Antimicrob. Agents Chemother. 43: 194-195 [Abstract] [Full Text]